Press Releases

The following are official statements issued by UsAgainstAlzheimer’s in response to major national policy actions, industry events, breaking news, or organizational achievements. Please see the UsAgainstAlzheimer’s press kit page for additional information. For media requests, please contact Jon Summers at

  • October 20, 2023

    Alzheimer’s Leaders Discuss How to Shift Science into Clinical Practice During National Alzheimer’s Summit

    The event furthered discussions on ensuring recent scientific breakthroughs benefit patients.

    Read more
  • October 13, 2023

    UsAgainstAlzheimer’s Celebrates CMS Decision to Expand Medicare Coverage for Additional PET Scans

    Policy change allows for earlier diagnosis for millions of seniors and better...

    Read more
  • August 16, 2023

    UsAgainstAlzheimer’s Urges CMS to Adopt Proposed Policy That Removes Restrictions on Medicare Coverage of PET Scans for Alzheimer’s Patients

     Increased coverage would provide Alzheimer’s patients and their families with more...

    Read more
  • July 21, 2023

    UsAgainstAlzheimer’s Statement on Tony Bennett’s Death

    UsAgainstAlzheimer’s chair and co-founder George Vradenburg released a statement on the death...

    Read more
  • July 18, 2023

    CMS Proposes Removal of Policy That Limits Medicare Coverage of PET Scans for Alzheimer’s Patients

    Proposal would make Medicare coverage of Leqembi possible for millions while increasing...

    Read more
  • July 18, 2023

    Hearing Aids and Other Technologies Slowed Cognitive Decline by 48%, Study Shows

    Hearing loss is one of six major risk factors associated with Alzheimer’s 

    Read more
  • July 17, 2023

    New Donanemab Data Demonstrates Momentum Toward Choice of Treatments for Alzheimer’s Patients

    Research shows no clinical progression for nearly half of early-stage patients at...

    Read more
  • July 06, 2023

    UsAgainstAlzheimer’s Applauds FDA Approval of Leqembi for Treatment of Early-Stage Alzheimer’s

    Medicare must now provide coverage for patients.

    Read more
  • June 13, 2023

    UsAgainstAlzheimer's Applauds Unanimous Leqembi Endorsement by FDA Advisory Committee and Encourages Speedy Access for Patients

    The Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs...

    Read more

Place & Brain Health Equity: Understanding the County-Level Impacts of Alzheimer’s

The effects of where people live, and the social determinants of health are under-recognized and under-appreciated in our national response to effectively treat and prevent Alzheimer's. This report found that deep social inequities exist in countries highly impacted by Alzheimer's among Latinos and Blacks.